GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 608
- Registration Number
- NCT01772147
- Locations
- 🇵🇱
GSK Investigational Site, Wroclaw, Poland
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 131
- Registration Number
- NCT01772199
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
Completed
- Conditions
- Herpes ZosterHerpes Zoster Vaccine
- Interventions
- Other: Data collection
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 395
- Registration Number
- NCT01772160
- Locations
- 🇮🇹
GSK Investigational Site, Rome, Italy
Bioequivalence Study of an Amoxicillin-Clavulanic
Phase 1
Completed
- Conditions
- Infections, Respiratory Tract
- Interventions
- Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT01772238
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes zoster vaccine (GSK 1437173A)Drug: Placebo
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 568
- Registration Number
- NCT01767467
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Bioequivalence Study of Cephalexin Suspension 250
Phase 1
Completed
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01767571
Bioequivalence Study of Cephalexin Tablets 1g
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01767584
Glucagon-like Peptide (GLP) Utilization and Safety
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: The GLP-1 receptor agonist usersOther: DPP-4 inhibitor usersOther: Other ADA users
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01767389
Bioequivalence Study of Cephalexin Suspension 125
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01767532
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: PhtD vaccine with/without adjuvantBiological: Pneumovax 23TMBiological: NaCl
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT01767402
- Locations
- 🇧🇪
GSK Investigational Site, Bruxelles, Belgium
© Copyright 2025. All Rights Reserved by MedPath